Inhibitors of translation initiation, such as rocaglate scaffold inhibitors, were shown to inhibit the oncogenic MYC-driven transcriptional program and abrogate myeloma growth in preclinical in vivo MM models [13]. Here, MYC is linked to Miyoshi myopathy.